Author
Larissa Prata
- Indexed works
- 13
- Total citations
- 4,166
- Active years
- 6
Collaborators
Works in the record
EBioMedicine 2019
Open access · CC-BY
Senolytics decrease senescent cells in humans: Preliminary report from a clinical trial of Dasatinib plus Quercetin in individuals with diabetic kidney disease
EBioMedicine 2019
Open access · CC-BY
Senolytics in idiopathic pulmonary fibrosis: Results from a first-in-human, open-label, pilot study
Aging Cell 2019
Open access · CC-BY
Targeting senescent cells alleviates obesity‐induced metabolic dysfunction
Aging Cell 2019
Open access · CC-BY
Aged‐senescent cells contribute to impaired heart regeneration
EBioMedicine 2023
Open access · OA
Senolytics dasatinib and quercetin in idiopathic pulmonary fibrosis: results of a phase I, single-blind, single-center, randomized, placebo-controlled pilot trial on feasibility and tolerability
EBioMedicine 2022
Open access · CC-BY
Orally-active, clinically-translatable senolytics restore α-Klotho in mice and humans
Aging 2021
Open access · CC-BY
SARS-CoV-2 causes senescence in human cells and exacerbates the senescence-associated secretory phenotype through TLR-3
EBioMedicine 2020
Open access · CC-BY
Corrigendum to ‘Senolytics decrease senescent cells in humans: Preliminary report from a clinical trial of Dasatinib plus Quercetin in individuals with diabetic kidney disease’ EBioMedicine 47 (2019) 446–456
Cell Metabolism 2022
Open access · OA
Targeting p21Cip1 highly expressing cells in adipose tissue alleviates insulin resistance in obesity
Journal of the American Geriatrics Society 2021
Open access · CC-BY
Fisetin for <scp>COVID</scp> ‐19 in skilled nursing facilities: Senolytic trials in the <scp>COVID</scp> era
Cell Metabolism 2025
Preprint · OA
Endothelial senescent-cell-specific clearance alleviates metabolic dysfunction in obese mice
Journal of Internal Medicine 2025
Open access · OA
Senotherapeutics for metabolic disease and diabetic complications
Innovation in Aging 2020
Open access · CC-BY